Omnipharma (Pty) Ltd, Is a South African privately owned company with its head office and main manufacturing plant in Johannesburg, South Africa. A manufacturer of Rapid diagnostic test medical devices. A Rapid diagnostic test (RDT) is a medical diagnostic test that is rapid and easy to perform. RDTs are suitable for preliminary or emergency medical screening and use in medical facilities with limited resources. In addition to its manufacturing ability, Omnipharma can source and promote disposable medical devices to private hospitals, public entities, and government entities.
Omnipharma is an entirely black-owned Level 1 contributor in the two South African Market and manufacturing company specializing in Diagnostic products used in medical practice. Its products are exported to various overseas countries, locally Omnipharma currently sells to all of the major hospital groups and majority of the government medical entities in South Africa.
Omnipharma is the sole local manufacturer of rapid diagnostic test medical products (RDT) in South Africa and is the market leader in the public sector as well as growing steadily in the private market.
Omnipharma was founded in 1999 as a Rapid Urine test Manufacturer.
In 2008, the Makromed business was acquired as a going concern.
In 2009, Omnipharma acquired the Rapimed manufacturing plant, primarily to increase its own production capacity as well as to make it the sole local manufacturer of urine analysis strips in South Africa.
Makromed was an ISO9001 and ISO13485 approved facility with CE mark was an added attraction. The trademarks Makromed and Uricheck were also secured.
The combined manufacturing facility was relocated to a new modern production facility.
The combined new production unit is designed to produce sufficient product to fulfill the Country’s needs for urine strips, both in the State and Private Sectors and also to expand its export business.
In 2010 the upgrading of the packaging and acquisition of injection molding equipment proved to be an important cost saving in the procurement of components.
The executive team has focused its efforts on consolidating Makromed and Rapimed into one business under Omnipharma, then relocating the production to a new site and validating the combined manufacturing processes by ensuring correct attention and investment in the manufacturing outputs.
Omnipharma represents a vibrant and viable local manufacturing operation with scope for diversification and expansion in the future.
Omnipharma is local market leader in the manufacture and supply of medical devices and products to the public and private health sector.